Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Zika virus disease
Zika virus disease
Zika virus disease
Synonyms: Zika virus infection
Synonyms: Zika virus infection
Synonyms: Zika virus infection
Drug discovery
2,266
papers
On emerging therapies
Rare infectious diseases
Zika virus disease
Overview
Zika virus is a mosquito-borne flavivirus transmitted primarily by Aedes aegypti mosquitoes, with additional routes including sexual contact, blood transfusion, and vertical transmission. While 80% of infections are asymptomatic [7][11], symptomatic cases present with rash, low-grade fever, arthralgia, conjunctivitis, or myalgia lasting 2–7 days [1][6][16]. The principal clinical concern is severe fetal neurodevelopmental anomalies (e.g., microcephaly) following prenatal infection and Guillain-Barré syndrome in adults [1][6][11].
Population
Burden
Global impact: Avg. 44,000 annual DALYs (2010–2019), predominantly in the Americas [4][9]
Neurological sequelae: Congenital Zika syndrome (5% risk in exposed pregnancies), Guillain-Barré syndrome (30x increased odds post-infection) [6][11][14]
Epidemiology: Peak incidence in 2016 (174 cases/100,000), though endemic transmission persists at lower levels [9][19]
Therapies
Symptomatic management: Rest, hydration, acetaminophen (avoid NSAIDs due to bleeding risk) [3][18]
Experimental approaches: Antivirals (Sofosbuvir, chloroquine), monoclonal antibodies, and peptide inhibitors in preclinical trials [3][8][13]
Prevention: Mosquito control, condom use during/after travel to endemic zones [6][11][17]
Categories: rare infectious diseases
Research Papers
2,266 drug discovery papers about Zika virus disease, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:
2,266 drug discovery papers about Zika virus disease, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-26 | Molecular Mechanisms of Zika Virus Entry into Host Cells.
The World Health Organization classifies mosquito-borne viruses as a major global public health threat with pandemic risk and urges all nations to strengthen pandemic preparedness. As a representative mosquito-borne flavivirus, ZIKV bears prominent pandemic capacity. Its distinctive neurotropic property and capability of vertical transmission create unique pathogenic hazards and transmission risks. Owing to the absence of approved vaccines and targeted antiviral therapeutics, the prevention and management of ZIKV outbreaks remain extremely challenging. Viral entry into host cells marks the very first step of productive ZIKV infection, and mechanistic investigations into this entry process lay an essential theoretical foundation for developing small-molecule agents that block ZIKV cellular entry. This review summarizes recent advances concerning ZIKV host receptor usage, membrane fusion cascades, and entry-targeted inhibitor development; systematically discusses existing inconsistencies and core controversies in cell type-dependent entry pathways, functionally redundant host receptor usage, especially the disputed AXL receptor, and unresolved molecular details of membrane fusion resulting from diverse experimental models and technical limitations; and proposes targeted future research directions to resolve these bottlenecks and clarify the context-dependent ZIKV entry mechanisms.
2026-09-11 | The CYP4G15-SORD-like-associated pathway promotes ovarian ZIKV infection and egg-associated viral RNA detection in Aedes albopictus.
Zika virus (ZIKV) can persist in mosquito populations through both horizontal and vertical transmission, and successful ovarian infection is a prerequisite for transgenerational spread. However, the mosquito host factors that regulate ovarian permissiveness and vertical transmission remain poorly characterized. Here, we investigated the role of cytochrome P450 4G15 (CYP4G15) in ZIKV infection and vertical transmission in Aedes albopictus and identified an associated downstream pathway involving SORD-like, a predicted sorbitol dehydrogenase-like gene. Expression profiling revealed that CYP4G15 exhibits distinct tissue-, developmental-, blood-feeding-, and infection-responsive patterns, with transient induction in ovaries during the early phase of ZIKV infection. RNA interference-mediated silencing of CYP4G15, followed by transcriptomic analysis and RT-qPCR validation, identified SORD-like (LOC109415972) as a candidate CYP4G15-associated gene. SORD-like was highly expressed in the fat body, strongly induced after blood feeding, and responsive to ZIKV challenge in ovarian tissues. Functional assays showed that knockdown of SORD-like significantly reduced early ovarian infection rate and viral RNA accumulation, while also decreasing conditional progeny egg-pool positivity rate and minimum egg infection rate, indicating reduced ZIKV RNA detection in progeny egg pools. SORD-like silencing did not alter CYP4G15 transcript levels, whereas CYP4G15 overexpression was associated with increased SORD-like transcript abundance and functionally compensated for the ovarian viral RNA phenotype caused by SORD-like knockdown. Together, these findings support a functional association between CYP4G15, SORD-like, and ovarian ZIKV infection, but do not establish direct transcriptional regulation or a strict linear epistatic relationship. Our findings reveal a CYP4G15-SORD-like-associated metabolic-regulatory pathway that links mosquito physiology to arbovirus persistence. Given that CYP4G-related pathways are often associated with environmental adaptation and insecticide resistance-associated physiology, this pathway may represent an important point of intersection between vector fitness and viral transmission. It may therefore serve as a candidate target for reducing egg-associated ZIKV RNA detection and ZIKV maintenance in Aedes albopictus populations.
2026-09-03 | A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral particle release and cytopathogenicity.
Flaviviruses are enveloped, positive-strand RNA viruses that cause millions of infections in the human population annually. Although Zika virus (ZIKV) had been detected in humans as early as the 1950s, its reemergence in South America in 2015 resulted in a global health crisis. While flaviviruses encode 10 proteins that can be post-translationally modified by host enzymes, little is known regarding post-translational modifications (PTMs) of the flavivirus proteome. We used mass spectrometry to comprehensively identify host-driven PTMs on the ZIKV proteome. This approach allowed us to identify 43 PTMs across 8 ZIKV proteins, including several that are highly conserved within the Flavivirus genus. Notably, we found two phosphosites on the ZIKV envelope protein that are functionally important for viral propagation. Both appear to regulate viral particle release, while one also impacts ZIKV cytopathogenicity. Additionally, we discovered host kinases that interact with ZIKV proteins and determined that Bosutinib-an FDA-approved tyrosine kinase inhibitor that targets some of these host kinases-impairs ZIKV growth, in part by blocking phosphorylation of a tyrosine residue on the envelope protein. Thus, we have defined a high-resolution map of host-driven PTMs on ZIKV proteins as well as cellular interacting kinases, uncovered novel mechanisms of host driven-regulation of ZIKV particle release and cytopathogenicity, and identified an FDA-approved inhibitor of ZIKV growth.
2026-08-19 | Neurodevelopment of children exposed and unexposed to Zika virus in pregnancy: a cross-sectional analysis.
This article aims to assess the neurodevelopment of children with and without in utero Zika virus (ZIKV) exposure, in the absence of microcephaly at birth, and to explore social and biological factors associated with develop- mental outcomes. Cross-sectional analysis of 172 children (94 ZIKV-exposed, 78 unexposed), aged 11-39 months, were evaluated using the Bayley Scales of Infant and Toddler Development. . Outcomes were classified as delayed (<70) or at risk (70-84) across cognitive, language, and motor domains. Exposure was confirmed by maternal RT-P- CR or neonatal IgM. Overall, 30.8% of children presented with developmental delay or risk in at least one domain. The most affected domain was language (26.7%). There were no statistically significant differences in delay frequency cognitive and motor domains.
2026-08-18 | Brain Organoids as Emerging Platforms for Modeling CNS Infections: Neuropathogenesis, Therapeutic Discovery, and Drug Delivery.
Neurotropic viruses remain a persistent global health challenge, and the mechanisms by which they damage the human brain are not yet fully understood. Animal models are often limited by human-specific aspects of CNS biology, whereas two-dimensional (2D) cell cultures cannot recapitulate the complex three-dimensional (3D) cellular interactions that occur during viral infection of the brain. Over the past decade, brain organoids derived from human stem cells have emerged as physiologically relevant models that address these limitations. These 3D cultures self-assemble into structures containing neurons, astrocytes, and progenitor cells arranged in patterns that resemble early brain development. This review examines the application of brain organoids to the study of infections caused by Zika virus (ZIKV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), herpes simplex virus (HSV), and human immunodeficiency virus type 1 (HIV-1). Studies were screened from PubMed and shortlisted based on their relevance to organoid-based CNS infection modeling, antiviral drug screening, CNS-targeted drug delivery, and neuroinflammation. Organoid-based antiviral screening has identified promising compounds from libraries containing more than 1,000 candidates. Drug delivery strategies are also discussed, with particular emphasis on nanoparticles, polymer-based carriers, and extracellular vesicles (EVs) evaluated in organoid and spheroid models for their ability to cross the blood-brain barrier (BBB) and deliver therapeutic cargo to neural cells. The roles of damage-associated and pathogen-associated molecular patterns (DAMPs and PAMPs) in neuroinflammation, complement evasion, and chronic post-infection damage, including long COVID, are also examined. Current limitations, including the lack of functional vasculature, incomplete BBB components, and reproducibility challenges, are discussed. Despite these limitations, CNS organoids bridge the gap between basic research and clinical application, advancing the development of effective therapies for viral infections of the brain.
vaccines
2026-09-08 | Evaluation of a Zika virus-like particle-based vaccine in a highly penetrant non-human primate model of congenital infection.
Zika virus (ZIKV) is an arthropod-borne Orthoflavivirus that caused a major outbreak in Central and South America in 2015-16. During that outbreak, ZIKV infection during pregnancy was associated with high rates of adverse outcomes, including miscarriage and a spectrum of neurological birth defects collectively termed congenital Zika syndrome (CZS). Ten years later, there are still no licensed ZIKV vaccines, underscoring the need for robust experimental models to evaluate vaccine efficacy against congenital disease. Here, we evaluated a highly pathogenic nonhuman primate pregnancy model for its ability to assess vaccine-mediated protection using a Zika virus-like particle (VLP) vaccine as a test platform. First, non-pregnant rhesus macaques (RM) were vaccinated with a prime-boost method to compare control, VLP alone, and VLP plus Alhydrogel (alum) adjuvant. Vaccination plus alum elicited strong neutralizing antibody responses and reduced viral dissemination compared to controls. Next, we evaluated the vaccine's protective efficacy against adverse pregnancy complications. Two cohorts of female RM were vaccinated with ZIKV-VLP adjuvanted with alum or alum alone prior to time-mated breeding. At gestational day (GD) 30 (mid first trimester), pregnant animals were challenged with ZIKV-DAK 41524, an African-lineage strain previously shown to induce frequent first-trimester pregnancy loss. Within the vaccinated cohort, two of three animals reached the study endpoint of GD 90 with no observed adverse pregnancy outcomes. One vaccinated animal experienced early pregnancy loss despite the absence of detectable virus in fetal or placental tissues. In the sham vaccine control pregnancy cohort, severe adverse outcomes included miscarriage and hydrops fetalis with widespread viral RNA and placental pathology in two animals. These results support a high risk of early pregnancy loss following African-lineage ZIKV-DAK 41524 infection in RM. This model can be further used to understand the complexities of placental immunological features underlying miscarriage following ZIKV infection.
2026-07-13 | Mouse models of Zika virus infection-induced placenta and fetal brain damage.
Zika virus (ZIKV) infection during pregnancy is associated with the development of Congenital Zika syndrome. The ZIKV epidemic in 2015 in South America exhibited an increased incidence of microcephaly cases in infants born to mothers who were infected during pregnancy, and infection in adults led to Guillain-Barré Syndrome. A growing body of literature demonstrates that the vertical transmission of ZIKV results in placental infection and injury. Further, ZIKV is transmitted to the fetus, specifically inducing apoptosis in neuronal progenitor cells, resulting in the development of microcephaly. This review summarizes recent advances in ZIKV infection, cell death, immune activation, and protective strategies in various mouse models. Specifically, we have reviewed recent studies on placental and fetal brain/head infections in mouse models, namely anti-IFNAR1 antibody-treated wild-type mice, Ifnar-deficient mice, Stat2-deficient mice, and humanized STAT2 knock-in mice. We also discussed the role of ZIKV infection-induced cell death, inflammation, interferon response, and associated immune-related outcomes in the placenta and fetal brain/head. In addition, we have reviewed recent advances in the development of vaccine candidates and potential therapeutic agents that protect against ZIKV-induced placental and fetal brain damage in preclinical models. In summary, our review of literature highlights key pathogenic mechanisms that drive ZIKV-induced placental and fetal brain/head injury, and protective strategies against ZIKV infection.
2026-05-13 | Strategies to enhance DNA vaccine efficacy against emerging arboviruses: lessons from ZIKA and Chikungunya viruses.
The mosquito-borne arboviruses Zika and Chikungunya pose serious health threats worldwide, often co-circulating and causing co-infections in Aedes endemic regions. While no licensed vaccine is currently available for Zika virus (ZIKV), recent progress has led to the approval of vaccines for Chikungunya virus (CHIKV) in few countries, highlighting the need for improved vaccine strategies. Zika virus (ZIKV) presents unique challenges, including its neurotropism, association with congenital abnormalities, and potential for sexual and vertical transmission, whereas Chikungunya virus (CHIKV) is characterized by viral persistence in joint-associated tissues, leading to chronic inflammatory manifestations such as long-term arthralgia, along with comparatively limited clinical trial data for vaccine candidates. DNA vaccines offer a promising platform since they are safe and easy to produce; but their immunogenicity in humans is limited. The rational use of adjuvants and optimized delivery systems is important for enhancing DNA vaccine efficacy. This review discusses current adjuvant classes, including Toll-like receptor (TLR) agonists, molecular adjuvants, and classical adjuvants, focusing on their mechanisms to enhance immune cell activation and adaptive immunity. We summarize preclinical and clinical findings on DNA vaccines for ZIKV and CHIKV, highlighting the synergy of adjuvants with different delivery technologies and discuss the rationale for multivalent DNA vaccine strategies to address co-circulating arboviral infections. Finally, we have identified research gaps and suggested a translational roadmap to accelerate the development of effective DNA vaccines against these emerging arboviruses.
2026-04-17 | Effects of candidate vaccines against Zika virus infection: A systematic review of the clinical trials.
The 2015-2016 Zika virus (ZIKV) pandemic revealed a pathogenic potential, including Guillain-Barré syndrome and Congenital Zika Syndrome (CZS). Despite the decline in incidence, the potential for future circulation and the absence of specific antivirals underscore continued scientific interest in prophylactic vaccine development. To synthesize evidence from clinical trials regarding the safety and preliminary immunogenicity of current ZIKV vaccine candidates. This systematic review followed PRISMA guidelines (CRD420251056463). Searches were performed in MEDLINE, Embase, Web of Science, SciELO, and LILACS for clinical trials published between 2015 and 2025. Risk of bias was assessed using the Cochrane RoB 2 tool. Ten Phase 1 clinical trials were included, evaluating four platforms: inactivated virus (ZPIV, TAK-426, VLA1601), DNA (GLS-5700, VRC5283), mRNA (mRNA-1325, mRNA-1893), and viral vector (Ad26.ZIKV.001). All candidates demonstrated acceptable safety profiles, with predominantly mild-to-moderate and transient adverse events (e.g., injection site pain, fatigue, and headache); no vaccine-related serious adverse events were reported. Most platforms induced robust neutralizing antibody responses. Specifically, TAK-426 showed immune persistence for up to two years, while mRNA-1893 maintained responses for 13 months. The viral vector vaccine (Ad26.ZIKV.001) achieved 100% seroconversion with a single dose. Previous orthoflavivirus exposure did not significantly hinder vaccine-induced immunogenicity. Most studies presented a low risk of bias. ZIKV vaccine candidates across diverse technological platforms are safe and highly immunogenic. The evidence of long-term durability and the success of single-dose or mRNA regimens support the progression of the most promising candidates to Phase 2/3 trials.
2026-04-01 | Integrative immunogenomic strategy for designing a multi-epitope vaccine against Zika and Dengue viruses.
Two of the most prevalent illnesses spread by mosquitoes are the Dengue virus (DENV) and the Zika virus (ZIKV), both of which belong to the Flaviviridae family. Co-infection with ZIKV and DENV has been reported worldwide, sometimes with dire consequences. Developing a single vaccine capable of protecting against both pathogens would therefore be highly beneficial. In this research, an in-silico immunology strategy was employed to construct a multi-epitope, multi-pathogen vaccine targeting both viruses. Considering that DENV and ZIKV share the same mosquito vector, Aedes aegypti, and that its salivary proteins can facilitate viral infection, eleven CTL epitopes, five B-cell antigenic determinants, and twelve HTL epitopes were chosen for the final vaccine. Our DENV and ZIKV vaccine have 567 amino acids and molecular mass is 58603.84 amu. An in-silico 3D modelling process and a structural explanation of the model followed docking and dynamics simulations utilizing human TLR7 and TLR5 with docking scores of -392.81 and − 370.88, respectively. The immune reaction simulation suggests that the suggested vaccination may cause a significant immune response that can protect against both DENV and ZIKV.
antibodies
2026-08-14 | Activation and Inhibition of Autophagy and the Lysosome: Potential Therapeutic Avenues for Prenatal Zika Virus Infection
Zika virus (ZIKV), a mosquito-borne flavivirus, has been found in 87 countries and territories. Global outbreaks peaked in 2016. Prenatal Zika virus infection was found to be associated with microcephaly, arthrogryposis, intracranial calcifications, fetal growth restriction, and fetal demise. The most severely affected children were diagnosed with congenital Zika syndrome, which impacts thousands worldwide. With no approved treatment or preventative measures for Zika virus, future viral outbreaks have the potential to cause epidemic levels of prenatal brain injury, as seen over the past 70 years. Therefore, there is a great need for a reliable and clinically translational experimental system that mimics the human condition of prenatal Zika virus infection. To this end, we developed a novel, humanized, immunocompetent preclinical system of virally induced brain injury from prenatal Zika virus infection, which ranges from mild to severe. Here, we describe the extent to which this system mirrors the human phenotypic spectrum. Using our thorough preclinical system, we find that prenatal Zika virus infection of mice impacts survival rate, anthropometric measurements, tissue formation, and neurological outcomes, all of which are typically affected by prenatal infection. Current and future applications include the identification of genetic or environmental modifiers of brain injury, molecular or mechanistic studies of pathogenesis, and preclinical evaluation of future therapies.
2026-08-07 | Generation and characterization of an anti ITGB4 monoclonal antibody that blocks Zika virus entry.
Zika virus (ZIKV) causes congenital disease and neurological complications, yet no approved vaccines or antivirals are available. Integrin β4 (ITGB4) has been identified as an entry receptor for ZIKV. Recombinant human ITGB4 ectodomain was expressed using a baculovirus-insect cell system and used to immunize BALB/c mice. Hybridoma screening identified monoclonal antibody 7C3. Binding affinity to ITGB4 was determined by biolayer interferometry. Epitope relationships between 7C3 and the previously reported anti-ITGB4 antibody 13H10 were assessed by competitive binding assay. Antiviral activity was evaluated in four cell lines by RT-qPCR quantification of cell-associated ZIKV RNA after antibody pretreatment and viral challenge. 7C3 bound ITGB4 with picomolar affinity (KD=30.9 pM) and high specificity. Competitive binding showed that 7C3 and 13H10 (KD=7.98 pM) recognize non-overlapping epitopes on ITGB4. Pretreatment with 7C3 significantly reduced cell-associated ZIKV RNA in all four cell lines compared with PBS and isotype controls. A second, independently generated anti-ITGB4 antibody with picomolar affinity can robustly block ZIKV entry across multiple cell types, including SY5Y neuroblastoma cells relevant to congenital neuropathology. The non-overlapping epitopes of 7C3 and 13H10 suggest potential for combination strategies to enhance ITGB4 blockade. High germline identity of the 7C3 variable regions (VH=94.46%, VL=95.82%) supports future humanization. These findings establish 7C3 as a host-directed antiviral candidate and provide a basis for ITGB4-targeting approaches against congenital ZIKV disease.
2026-05-21 | E-protein variability in Zika virus strains: A possible new O-glycosylation site and its implications.
Background and objectives Zika virus (ZIKV) is a flavivirus transmitted by the bite of infected Aedes mosquito. In 2015-16, Brazil reported cases of ZIKV virus infection followed by Guillain-Barre syndrome and congenital birth defects. India has reported ZIKV virus infections sporadically since 2016, without adverse events. This prompted us to conduct this in-silico investigation and identify reasons for this variation. The objective was to study ZIKV envelope protein (E-protein) to identify possible mutations and their potential role in virus entry into the host cell. Methods Using multiple sequence alignments, we compared the genomic sequences from eleven ZIKV strains with maximum genomic data available in the NCBI database, followed by phylogenetic analysis. ZIKV E-protein structures with mutations were generated using AlphaFold and used for molecular dynamic simulation, followed by protein 3D structure and residues interaction analysis. Results We identified 2 major ZIKV clades - ZIKV Senegal strain (African lineage, Accession No. MF510857, 1984) is an ancestral strain representing one clade, while the remaining strains belong to the second major clade, with the Indian strain being closest to the Senegal strain genomically. The Senegal strain also has a significant mutation at residue no. 120 of the E-protein (Alanine to Threonine), which is absent in other strains. Interpretation and conclusions We found a mutation in the ZIKV Senegal strain at residue no. 120 (Alanine Threonine), here Threonine is interacting with Serine residue at position 64. This interaction is known for post-translational O-glycosylation of E-protein, which may reduce the efficacy of envelope-based therapies. To the best of our knowledge, this is the first report of a putative O-glycosylation site on the E-protein of a ZIKV strain, which is an important therapeutic target, and our finding needs further in vitro validation.
2026-05-04 | Dual role of Japanese encephalitis virus fusion loop peptide antibodies in Zika virus infection.
Zika virus (ZIKV) is a key member of the Flavivirus genus that has emerged as a major global public health concern. The fusion loop region (residues 98-110), located within domain II of the envelope protein, is highly conserved among flaviviruses, including ZIKV and Japanese encephalitis virus (JEV). However, the functional consequences of such conservation for cross-reactive immunity remains unclear. Here, we integrated bioinformatic analyses, functional assays in vitro and mouse models in vivo to systematically determine the effects of antibodies directed against the JEV fusion loop (FL) region on ZIKV infection. Sequence alignment and structural analysis revealed complete amino acid identity and almost identical three-dimensional conformations between the FL regions of the two viruses, providing a molecular basis for cross-reactivity. Antisera generated against the JEV FL region recognized ZIKV particles and displayed concentration-dependent bidirectional effects. Increased and decreased antibody levels respectively neutralized viral entry and replication, and facilitated infection via antibody-dependent enhancement (ADE). These effects were confirmed in vivo, in which high and low antibody doses reduced tissue pathology and improved survival, and increased viremia and exacerbated inflammatory responses, respectively. These findings highlight the importance of antibody concentration in determining whether cross-reactive responses to conserved structural elements engender neutralization or enhancement response. Our findings provide experimental evidence for assessing ZIKV susceptibility in JEV-vaccinated populations and offer structural insights for designing flavivirus vaccines that maximize protection while minimizing ADE risk. These findings further highlight potential pathogenic and clinical considerations for optimizing vaccine formulations to reduce cross-reactive enhancement risks.
2026-03-10 | SLC3A2 promotes early-stage of Zika virus infection in human placental cells and astrocytes
Abstract Background: Zika virus (ZIKV) has been associated with neonatal microcephaly or atypical Guillain-Barré syndrome in adults since 2016. However, despite considerable progress in understanding the biology and pathogenesis of ZIKV infection, little is known about its entry factors. This study aimed to identify host-cell proteins essential for ZIKV entry enriched by labeled viral envelope particles. The identification of solute carrier family 3 member 2 (SLC3A2) (CD98 heavy chain) through this approach highlights its potential as a novel target for therapeutic intervention against ZIKV. Methods: Gene editing via CRISPR-Cas9 and classical virological experiments were performed to identify SLC3A2 functions in ZIKV entry and infection processes. Immunofluorescence, quantitative real-time PCR (RT-qPCR), and western blotting technologies were further used to detect viral proteins and genomes. Besides, coimmunoprecipitation and protein/antibody blocking assay were also conducted to identify direct interactions between SLC3A2 and the ZIKV envelope protein. Results: Several human membrane proteins were overexpressed in HEK293 T cells, but only SLC3A2 could significantly promote ZIKV entry into host cells by two- to three- fold compared with the control. During authentic ZIKV infection, the genetic ablation of SLC3A2 in SLC3A2-KO1 JEG-3 cells reduced the viral infection rate to 59.00% ± 5.10% of the wild-type level (100.00% ± 4.97%) ( P < 0.001), but its overexpression increased the susceptibility of human placenta- and brain-derived cell lines to the virus. SLC3A2 overexpression increased attached ZIKV levels to 3.4-fold of the control (3.423 ± 0.715 vs . 1.000 ± 0.897, P < 0.001) and internalized ZIKV levels to 1.7-fold of the control (3.782 ± 0.512 vs . 2.293 ± 0.272, P = 0.013) due to direct interaction with the ZIKV envelope protein in U-251MG cells. Our data further showed the close association of SLC3A2 with the ZIKV envelope protein via its extracellular domain during authentic viral infection. Notably, SLC3A2 ectodomain decoys and blocking antibodies markedly reduced ZIKV infection rather than affecting influenza A virus infection. Conclusion: SLC3A2 promotes ZIKV infection in placenta- or brain-derived cells by directly interacting with the ZIKV envelope protein and improving virus entry. SLC3A2 may be implicated in early-phase ZIKV infection as its entry factor, thereby identifying a potential therapeutic target and a basis for formulating antiviral strategies against ZIKV.
proteins
2026-08-07 | Antiviral efficacy of Trappin-2/Elafin against Zika virus in the human keratinocyte HaCaT cell line.
Zika virus (ZIKV) is primarily transmitted through mosquito bites, and the skin acts as the initial site of viral entry into the host. Consequently, resident skin cells are among the first targets of infection. The epidermis, mainly composed of keratinocytes, can mount an antiviral response against arboviruses through the production of interferons, interferon-stimulated genes, cytokines, and antimicrobial peptides (AMPs), including the Trappin-2/Elafin (Tr2/E) peptide. However, the antiviral activity of Tr2/E during ZIKV infection remains poorly understood, therefore, this study aimed to investigate the antiviral activity of Tr2/E in human keratinocytes during ZIKV infection. In this study, we evaluated the permissiveness of the human keratinocyte cell line HaCaT to infection with a Mexican isolate of ZIKV and observed that these cells support productive viral infection. We then assessed whether ZIKV infection induces endogenous expression of Tr2/E. Tr2/E transcripts were detected in infected cells and showed increased expression over time post-infection, which correlated with the presence of its corresponding protein. Furthermore, we evaluated the antiviral potential of this peptide through exogenous treatment of infected keratinocytes. A significant reduction in ZIKV infection following Tr2/E treatment was observed. Collectively, these findings provide additional insight into the involvement of AMPs in the antiviral response to ZIKV infection and highlight Tr2/E as a potential antiviral factor.
2026-06-09 | Human dermal fibroblast-derived factors from sequential DENV-2 and ZIKV coinfection drive dendritic cell maturation and antiviral responses.
Dengue virus (DENV) and Zika virus (ZIKV) are among the most prevalent mosquito-borne viruses worldwide. These viruses co-circulate in the same geographical regions and share the same mosquito vectors, enabling concurrent or sequential transmission to humans within a short period. During the early phase of arbovirus infection, skin-resident cells constitute the first line of defense following viral inoculation, yet the immunological events in the skin microenvironment during early DENV-ZIKV coinfection are not well understood. This study aimed to investigate the response of primary human dermal fibroblasts (HDFs) to DENV-ZIKV coinfection and to determine how these responses influence bystander immune cells within an in vitro. We demonstrated that sequential infection with DENV-2 followed by ZIKV significantly increased the expression of pro-inflammatory cytokines (IL-6, IL-8, IL-1β), leukocyte migration-associated chemokine (CXCL10), and antiviral mediators (IFN-β and IFN-λ) in HDFs. Primary monocyte-derived dendritic cells (moDCs) exposed to soluble mediators from sequentially coinfected HDFs exhibited greater activation marker expression compared with simultaneous coinfection or monoinfection conditions. Furthermore, these mediators conferred antiviral effects against both DENV-2 and ZIKV infection in treated moDCs. These findings highlight the important role of dermal fibroblasts in shaping adaptive immunity and limiting viral spread during DENV and ZIKV coinfection.
2026-05-29 | ACSS2-mediated MYH9 crotonylation drives Zika virus-induced vascular smooth muscle cell phenotypic switching.
Zika virus (ZIKV) infection represents an emerging cause of cardiovascular pathology, yet the molecular mechanisms driving virus-induced vascular injury remain incompletely defined. This investigation identifies a crotonylation pathway underlying ZIKV-induced vascular disease. We demonstrate that ZIKV infection upregulates the metabolic regulator ACSS2, consequently elevating intracellular crotonyl-CoA levels. This metabolic shift drives lysine crotonylation of the cytoskeletal protein MYH9 at the critical K82 residue, triggering a pathological transition of vascular smooth muscle cells from contractile to synthetic phenotypes. This cellular reprogramming promotes aortic injury across multiple animal models, including northern pig-tailed macaques and A129 mice. Genetic ablation of ACSS2 substantially attenuated both the phenotypic switching and disease progression. Furthermore, we developed a targeted therapeutic peptide that effectively inhibits MYH9-K82 crotonylation and mitigates pathological vascular remodeling. These findings not only elucidate ACSS2-mediated protein crotonylation as a fundamental mechanism in ZIKV-induced vasculopathy but also present a promising precision therapeutic strategy for treating virus-induced proliferative vascular diseases.
2026-03-31 | Breaking barriers and beyond: Mechanisms and pathological implications of Zika virus traversal across blood-tissue interfaces.
Blood-tissue barriers are specialized interfaces that safeguard organ homeostasis by restricting pathogen dissemination. Zika virus (ZIKV), an emerging flavivirus of global concern, exhibits an exceptional ability to breach multiple barriers-including the blood-brain, blood-placental, blood-testis, and blood-retinal barriers-enabling neuroinvasion, vertical and sexual transmission, and ocular disease. ZIKV employs diverse strategies to cross these barriers: receptor-mediated entry, disruption of tight junctions, and hijacking immune cells or extracellular vesicles as viral carriers. Adaptive mutations further refine tissue tropism and enhance barrier traversal efficiency. Insights from cell culture, organoid, animal, and ex vivo tissue models reveal not only the conserved and tissue-specific mechanisms of barrier penetration but also the downstream pathological consequences in the affected organs. Understanding how ZIKV breaches these interfaces and induces organ-specific pathology deepens our knowledge of host-pathogen interactions and provides a framework for designing barrier-protective and disease-mitigating strategies against ZIKV and other pathogens that breach blood-tissue barriers.
2026-02-09 | Interferon lambda signaling to maternal dendritic cells protects against congenital Zika virus infection.
Interferon lambda (IFN-λ, type III IFN) mediates antiviral immunity at anatomic barriers, including the maternal-fetal interface. To investigate the effects of IFN-λ during congenital Zika virus (ZIKV) infection, we infected mice lacking the IFN-αβ receptor (Ifnar1 -/-) or both the IFN-αβ and IFN-λ receptors (Ifnar1 -/- Ifnlr1 -/-) at E9 and found that loss of maternal IFN-λ signaling resulted in greater transplacental transmission. We used HiPlex RNAscope on entire gravid uteruses and found that IFN-λ was expressed more proximal to the site of ZIKV infection in Ifnar1 -/- dams compared to Ifnar1 -/- Ifnlr1 -/- dams. We performed immunophenotyping of the placenta and uterus by flow cytometry and found a decrease in dendritic cells and NK cells in the uterus of Ifnar1 -/- Ifnlr1 -/- dams compared to Ifnar1 -/- dams, but NK cell depletion did not impact fetal infection. Using conditional knockout mice, we identified maternal dendritic cells as the key IFN-λ responsive cell type mediating protection against ZIKV congenital infection.
other
2026-08-21 | Tunneling nanotubes contribute to Zika virus pathogenesis at the maternal-fetal interface in vivo.
Zika virus (ZIKV) infection during pregnancy can result in severe fetal outcomes, yet the mechanisms of transplacental dissemination remain incompletely defined. We previously showed that ZIKV induces tunneling nanotubes (TNTs), actin-rich intercellular conduits that enable direct cell-to-cell transfer of viral components. Here, we investigated the in vivo role of TNTs in ZIKV maternal-fetal transmission using complementary pregnancy models. A TNT-deficient ZIKV mutant (ZIKVΔTNT), harboring a change between residues 40 and 52 of the nonstructural protein 1 (NS1), showed markedly reduced viral dissemination to maternal and fetal tissues across all models tested, whereas the TNT-competent ZIKV established a robust infection. ZIKVΔTNT infection was associated with reduced placental pathology, altered junctional-to-labyrinth architecture, improved placental efficiency, and protection from fetal growth restriction. Loss of TNT-forming capacity also limited viral persistence despite maternal type III interferon (IFN-λ) responses, suggesting a role for TNTs in immune evasion. Together, these findings provide in vivo evidence that TNTs are a key mechanism by which ZIKV enhances dissemination, promotes placental dysfunction, and drives fetal pathogenesis.IMPORTANCEZika virus infection during pregnancy can cause severe fetal abnormalities, yet how the virus overcomes the placenta remains incompletely understood. Here, we show that ZIKV exploits direct intercellular connections called tunneling nanotubes (TNTs) to facilitate cell-to-cell transmission and impact placental infection and fetal outcomes. Using multiple pregnancy models, we demonstrate that viruses capable of forming these structures disseminate more efficiently, damage the placenta, and lead to fetal growth restriction, whereas TNT-deficient viruses show reduced infection and milder disease. Importantly, TNT-mediated dissemination is associated with viral persistence despite maternal interferon responses, suggesting a role in immune evasion. These findings identify TNTs as a previously underappreciated pathway of viral transmission during pregnancy and suggest new therapeutic targets. More broadly, TNTs may contribute to the pathogenesis of other vertically transmitted or emerging viral infections.
2026-06-06 | Zika virus as an oncolytic therapy.
Glioblastoma (GBM) is a common, aggressive, primary brain tumor. New therapies are needed to improve outcomes in patients with this disease. One such approach which has shown preclinical promise is the use of genetically engineered Zika virus for oncolytic virotherapy. Zika virus is an enveloped, positive-sense, single-stranded RNA virus and is spread by mosquitoes of the Aedes genus. Most infections with Zika virus in adults are asymptomatic. However, primary infection with Zika virus early during pregnancy can cause fetal congenital defects. This phenomenon, termed congenital Zika syndrome, is thought to be the result of infection of fetal neural stem cells. The development of Zika virus as an oncolytic for GBM arose from the discovery that Zika virus infects and kills GBM stem cells. GBM stem cells have similarities to fetal neural stem cells and are a subpopulation of cells within the tumor that are refractory to treatment and likely drive tumor persistence and re-occurrence. In preclinical models of GBM, infection with Zika virus triggers immune-mediated clearance of orthotopically transplanted tumors and leads to development of immunological memory. The propensity of Zika virus to infect GBM stem cells along with limited systemic toxicities and transmissibility make Zika virus an ideal candidate for development as an oncolytic therapy.
2026-05-21 | A CRISPR activation screen identifies SPART as a pan-orthoflavivirus restriction factor.
Orthoflaviviruses, including Zika (ZIKV), dengue, Japanese encephalitis, and West Nile viruses, cause diverse clinical syndromes and threaten human health. Identifying factors that inhibit orthoflavivirus infection could lead to antiviral countermeasures. Here, we conducted a genome-wide CRISPR activation screen and identified the host gene SPART (Spartin/SPG20) as a restriction factor against ZIKV and other orthoflaviviruses. SPART interacts with and disrupts the endosomal localization of Itchy E3-ubiquitin ligase (ITCH), which we determine ubiquitinates the ZIKV capsid, thereby triggering uncoating. Loss of SPART enhances ZIKV replication, an effect not observed in SPART-ITCH double knockout mutants. Maternal ZIKV infection of Spg20-/- mice results in heightened maternal and fetal viral loads and greater fetal abnormalities, whereas infection of Itch-/- mice yields opposite outcomes. Similar results were observed in these gene-edited mice upon infection with related orthoflaviviruses. Overall, this approach identified a broad orthoflavivirus restriction factor, providing a potential target against these emerging pathogenic viruses.
2026-05-15 | MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.
Zika virus (ZIKV) remains a significant public health threat due to its pronounced neurotropism linked to Congenital Zika Syndrome (CZS). Paradoxically, the same neurotropism also provides a unique opportunity for exploiting ZIKV as an oncolytic agent against malignant brain tumors such as glioma. However, achieving precise control of ZIKV replication in specific cell types or tissues remains a major challenge. Here, we show that the brain-specific and enriched microRNA, miR-124, is highly expressed in neural progenitor cells (NPCs) and neurons, but minimally expressed in glioma stem cells (GSCs) and differentiated glioma stem cells (DGCs). Based on these observations, we engineered a recombinant ZIKV containing a miR-124 target sequence (miR-124T) inserted into the 3' untranslated region (UTR) of the viral genome, generating the virus designated ZIKV-miR124T. ZIKV-miR124T exhibited a significantly attenuated phenotype across multiple mouse models, including adult A129 mice, BALB/c neonates, and pregnant mice. Importantly, in an orthotopic glioma model, ZIKV-miR124T retained potent oncolytic activity while showing a markedly improved safety profile. Viral replication was strictly confined in the tumor region, with a ~1,000-fold reduction in viral load in non-tumoral brain regions compared to the well-established live-attenuated ZIKV (ZIKV-LAV). Furthermore, a single immunization with ZIKV-miR124T conferred effective protection against lethal ZIKV challenge and significantly reduced vertical transmission in pregnant mice. Collectively, our findings establish a strong proof of concept for a rational, miRNA-guided strategy to generate a next-generation ZIKV platform with dual potential as a safe live-attenuated vaccine and a precisely regulated oncolytic virus. This study presents a crucial advancement in controlling the safety and function of neurotropic viruses. We engineered a dual-purpose ZIKV, ZIKV-miR124T, which is regulated by the brain-specific microRNA, miR-124. This design forces the virus to strongly self-suppress in healthy neural tissue, solving a major safety concern for ZIKV-based therapies. ZIKV-miR124T is shown to be a potent oncolytic agent against malignant glioma while also serving as a highly effective, safe live-attenuated vaccine against ZIKV infection, reducing vertical transmission to the fetus. Our work provides a strong demonstration of utilizing microRNA regulation to achieve precise viral tropism and attenuation, offering a valuable, generalizable strategy for the development of safer and more effective viral therapies and vaccines against neurotropic pathogens.
2026-04-01 | The Upregulation of Anti-apoptotic BIRC3 Expression Facilitates Zika Virus Infection
Objective: The aim of this study was to investigate the apoptotic gene expression profile and to identify the genes involved in apoptosis and ZIKV infection. Materials and Methods: SH-SY5Y cell line was infected with ZIKV at an MOI of 5. The cells were stained with Annexin V and propidium iodide to determine apoptosis. A real-time polymerase chain reaction array was employed to determine the apoptotic gene expression profile in a ZIKV-infected SH-SY5Y cell line. Western blot analysis was performed to confirm the expression of BIRC3 in both SH-SY5Y and A549 cell lines. Knockdown of the BIRC3 was done in ZIKV-infected A549 cell line using BIRC3 -specific siRNA. The ZIKV production was measured by focus-forming unit assay. Results: Apoptotic genes in both extrinsic and intrinsic pathways, such as TNF-α, TRAIL, FAS, CASP8, CASP9, and BIRC3, were found to be upregulated. The anti-apoptotic gene BIRC3 was selected and found to be upregulated at the protein level in both ZIKV-infected SH-SY5Y and ZIKV-infected A549 cell lines. Knockdown of the BIRC3 gene in ZIKV-infected A549 cell line decreased Zika virus NS1 protein expression and Zika virion production. Conclusion: The upregulation of anti-apoptotic BIRC3 expression facilitates Zika virus infection.
small molecules
2026-09-26 | Molecular Mechanisms of Zika Virus Entry into Host Cells.
The World Health Organization classifies mosquito-borne viruses as a major global public health threat with pandemic risk and urges all nations to strengthen pandemic preparedness. As a representative mosquito-borne flavivirus, ZIKV bears prominent pandemic capacity. Its distinctive neurotropic property and capability of vertical transmission create unique pathogenic hazards and transmission risks. Owing to the absence of approved vaccines and targeted antiviral therapeutics, the prevention and management of ZIKV outbreaks remain extremely challenging. Viral entry into host cells marks the very first step of productive ZIKV infection, and mechanistic investigations into this entry process lay an essential theoretical foundation for developing small-molecule agents that block ZIKV cellular entry. This review summarizes recent advances concerning ZIKV host receptor usage, membrane fusion cascades, and entry-targeted inhibitor development; systematically discusses existing inconsistencies and core controversies in cell type-dependent entry pathways, functionally redundant host receptor usage, especially the disputed AXL receptor, and unresolved molecular details of membrane fusion resulting from diverse experimental models and technical limitations; and proposes targeted future research directions to resolve these bottlenecks and clarify the context-dependent ZIKV entry mechanisms.
2026-09-11 | The CYP4G15-SORD-like-associated pathway promotes ovarian ZIKV infection and egg-associated viral RNA detection in Aedes albopictus.
Zika virus (ZIKV) can persist in mosquito populations through both horizontal and vertical transmission, and successful ovarian infection is a prerequisite for transgenerational spread. However, the mosquito host factors that regulate ovarian permissiveness and vertical transmission remain poorly characterized. Here, we investigated the role of cytochrome P450 4G15 (CYP4G15) in ZIKV infection and vertical transmission in Aedes albopictus and identified an associated downstream pathway involving SORD-like, a predicted sorbitol dehydrogenase-like gene. Expression profiling revealed that CYP4G15 exhibits distinct tissue-, developmental-, blood-feeding-, and infection-responsive patterns, with transient induction in ovaries during the early phase of ZIKV infection. RNA interference-mediated silencing of CYP4G15, followed by transcriptomic analysis and RT-qPCR validation, identified SORD-like (LOC109415972) as a candidate CYP4G15-associated gene. SORD-like was highly expressed in the fat body, strongly induced after blood feeding, and responsive to ZIKV challenge in ovarian tissues. Functional assays showed that knockdown of SORD-like significantly reduced early ovarian infection rate and viral RNA accumulation, while also decreasing conditional progeny egg-pool positivity rate and minimum egg infection rate, indicating reduced ZIKV RNA detection in progeny egg pools. SORD-like silencing did not alter CYP4G15 transcript levels, whereas CYP4G15 overexpression was associated with increased SORD-like transcript abundance and functionally compensated for the ovarian viral RNA phenotype caused by SORD-like knockdown. Together, these findings support a functional association between CYP4G15, SORD-like, and ovarian ZIKV infection, but do not establish direct transcriptional regulation or a strict linear epistatic relationship. Our findings reveal a CYP4G15-SORD-like-associated metabolic-regulatory pathway that links mosquito physiology to arbovirus persistence. Given that CYP4G-related pathways are often associated with environmental adaptation and insecticide resistance-associated physiology, this pathway may represent an important point of intersection between vector fitness and viral transmission. It may therefore serve as a candidate target for reducing egg-associated ZIKV RNA detection and ZIKV maintenance in Aedes albopictus populations.
2026-09-03 | A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral particle release and cytopathogenicity.
Flaviviruses are enveloped, positive-strand RNA viruses that cause millions of infections in the human population annually. Although Zika virus (ZIKV) had been detected in humans as early as the 1950s, its reemergence in South America in 2015 resulted in a global health crisis. While flaviviruses encode 10 proteins that can be post-translationally modified by host enzymes, little is known regarding post-translational modifications (PTMs) of the flavivirus proteome. We used mass spectrometry to comprehensively identify host-driven PTMs on the ZIKV proteome. This approach allowed us to identify 43 PTMs across 8 ZIKV proteins, including several that are highly conserved within the Flavivirus genus. Notably, we found two phosphosites on the ZIKV envelope protein that are functionally important for viral propagation. Both appear to regulate viral particle release, while one also impacts ZIKV cytopathogenicity. Additionally, we discovered host kinases that interact with ZIKV proteins and determined that Bosutinib-an FDA-approved tyrosine kinase inhibitor that targets some of these host kinases-impairs ZIKV growth, in part by blocking phosphorylation of a tyrosine residue on the envelope protein. Thus, we have defined a high-resolution map of host-driven PTMs on ZIKV proteins as well as cellular interacting kinases, uncovered novel mechanisms of host driven-regulation of ZIKV particle release and cytopathogenicity, and identified an FDA-approved inhibitor of ZIKV growth.
2026-08-19 | Neurodevelopment of children exposed and unexposed to Zika virus in pregnancy: a cross-sectional analysis.
This article aims to assess the neurodevelopment of children with and without in utero Zika virus (ZIKV) exposure, in the absence of microcephaly at birth, and to explore social and biological factors associated with develop- mental outcomes. Cross-sectional analysis of 172 children (94 ZIKV-exposed, 78 unexposed), aged 11-39 months, were evaluated using the Bayley Scales of Infant and Toddler Development. . Outcomes were classified as delayed (<70) or at risk (70-84) across cognitive, language, and motor domains. Exposure was confirmed by maternal RT-P- CR or neonatal IgM. Overall, 30.8% of children presented with developmental delay or risk in at least one domain. The most affected domain was language (26.7%). There were no statistically significant differences in delay frequency cognitive and motor domains.
2026-08-18 | Brain Organoids as Emerging Platforms for Modeling CNS Infections: Neuropathogenesis, Therapeutic Discovery, and Drug Delivery.
Neurotropic viruses remain a persistent global health challenge, and the mechanisms by which they damage the human brain are not yet fully understood. Animal models are often limited by human-specific aspects of CNS biology, whereas two-dimensional (2D) cell cultures cannot recapitulate the complex three-dimensional (3D) cellular interactions that occur during viral infection of the brain. Over the past decade, brain organoids derived from human stem cells have emerged as physiologically relevant models that address these limitations. These 3D cultures self-assemble into structures containing neurons, astrocytes, and progenitor cells arranged in patterns that resemble early brain development. This review examines the application of brain organoids to the study of infections caused by Zika virus (ZIKV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), herpes simplex virus (HSV), and human immunodeficiency virus type 1 (HIV-1). Studies were screened from PubMed and shortlisted based on their relevance to organoid-based CNS infection modeling, antiviral drug screening, CNS-targeted drug delivery, and neuroinflammation. Organoid-based antiviral screening has identified promising compounds from libraries containing more than 1,000 candidates. Drug delivery strategies are also discussed, with particular emphasis on nanoparticles, polymer-based carriers, and extracellular vesicles (EVs) evaluated in organoid and spheroid models for their ability to cross the blood-brain barrier (BBB) and deliver therapeutic cargo to neural cells. The roles of damage-associated and pathogen-associated molecular patterns (DAMPs and PAMPs) in neuroinflammation, complement evasion, and chronic post-infection damage, including long COVID, are also examined. Current limitations, including the lack of functional vasculature, incomplete BBB components, and reproducibility challenges, are discussed. Despite these limitations, CNS organoids bridge the gap between basic research and clinical application, advancing the development of effective therapies for viral infections of the brain.
vaccines
2026-09-08 | Evaluation of a Zika virus-like particle-based vaccine in a highly penetrant non-human primate model of congenital infection.
Zika virus (ZIKV) is an arthropod-borne Orthoflavivirus that caused a major outbreak in Central and South America in 2015-16. During that outbreak, ZIKV infection during pregnancy was associated with high rates of adverse outcomes, including miscarriage and a spectrum of neurological birth defects collectively termed congenital Zika syndrome (CZS). Ten years later, there are still no licensed ZIKV vaccines, underscoring the need for robust experimental models to evaluate vaccine efficacy against congenital disease. Here, we evaluated a highly pathogenic nonhuman primate pregnancy model for its ability to assess vaccine-mediated protection using a Zika virus-like particle (VLP) vaccine as a test platform. First, non-pregnant rhesus macaques (RM) were vaccinated with a prime-boost method to compare control, VLP alone, and VLP plus Alhydrogel (alum) adjuvant. Vaccination plus alum elicited strong neutralizing antibody responses and reduced viral dissemination compared to controls. Next, we evaluated the vaccine's protective efficacy against adverse pregnancy complications. Two cohorts of female RM were vaccinated with ZIKV-VLP adjuvanted with alum or alum alone prior to time-mated breeding. At gestational day (GD) 30 (mid first trimester), pregnant animals were challenged with ZIKV-DAK 41524, an African-lineage strain previously shown to induce frequent first-trimester pregnancy loss. Within the vaccinated cohort, two of three animals reached the study endpoint of GD 90 with no observed adverse pregnancy outcomes. One vaccinated animal experienced early pregnancy loss despite the absence of detectable virus in fetal or placental tissues. In the sham vaccine control pregnancy cohort, severe adverse outcomes included miscarriage and hydrops fetalis with widespread viral RNA and placental pathology in two animals. These results support a high risk of early pregnancy loss following African-lineage ZIKV-DAK 41524 infection in RM. This model can be further used to understand the complexities of placental immunological features underlying miscarriage following ZIKV infection.
2026-07-13 | Mouse models of Zika virus infection-induced placenta and fetal brain damage.
Zika virus (ZIKV) infection during pregnancy is associated with the development of Congenital Zika syndrome. The ZIKV epidemic in 2015 in South America exhibited an increased incidence of microcephaly cases in infants born to mothers who were infected during pregnancy, and infection in adults led to Guillain-Barré Syndrome. A growing body of literature demonstrates that the vertical transmission of ZIKV results in placental infection and injury. Further, ZIKV is transmitted to the fetus, specifically inducing apoptosis in neuronal progenitor cells, resulting in the development of microcephaly. This review summarizes recent advances in ZIKV infection, cell death, immune activation, and protective strategies in various mouse models. Specifically, we have reviewed recent studies on placental and fetal brain/head infections in mouse models, namely anti-IFNAR1 antibody-treated wild-type mice, Ifnar-deficient mice, Stat2-deficient mice, and humanized STAT2 knock-in mice. We also discussed the role of ZIKV infection-induced cell death, inflammation, interferon response, and associated immune-related outcomes in the placenta and fetal brain/head. In addition, we have reviewed recent advances in the development of vaccine candidates and potential therapeutic agents that protect against ZIKV-induced placental and fetal brain damage in preclinical models. In summary, our review of literature highlights key pathogenic mechanisms that drive ZIKV-induced placental and fetal brain/head injury, and protective strategies against ZIKV infection.
2026-05-13 | Strategies to enhance DNA vaccine efficacy against emerging arboviruses: lessons from ZIKA and Chikungunya viruses.
The mosquito-borne arboviruses Zika and Chikungunya pose serious health threats worldwide, often co-circulating and causing co-infections in Aedes endemic regions. While no licensed vaccine is currently available for Zika virus (ZIKV), recent progress has led to the approval of vaccines for Chikungunya virus (CHIKV) in few countries, highlighting the need for improved vaccine strategies. Zika virus (ZIKV) presents unique challenges, including its neurotropism, association with congenital abnormalities, and potential for sexual and vertical transmission, whereas Chikungunya virus (CHIKV) is characterized by viral persistence in joint-associated tissues, leading to chronic inflammatory manifestations such as long-term arthralgia, along with comparatively limited clinical trial data for vaccine candidates. DNA vaccines offer a promising platform since they are safe and easy to produce; but their immunogenicity in humans is limited. The rational use of adjuvants and optimized delivery systems is important for enhancing DNA vaccine efficacy. This review discusses current adjuvant classes, including Toll-like receptor (TLR) agonists, molecular adjuvants, and classical adjuvants, focusing on their mechanisms to enhance immune cell activation and adaptive immunity. We summarize preclinical and clinical findings on DNA vaccines for ZIKV and CHIKV, highlighting the synergy of adjuvants with different delivery technologies and discuss the rationale for multivalent DNA vaccine strategies to address co-circulating arboviral infections. Finally, we have identified research gaps and suggested a translational roadmap to accelerate the development of effective DNA vaccines against these emerging arboviruses.
2026-04-17 | Effects of candidate vaccines against Zika virus infection: A systematic review of the clinical trials.
The 2015-2016 Zika virus (ZIKV) pandemic revealed a pathogenic potential, including Guillain-Barré syndrome and Congenital Zika Syndrome (CZS). Despite the decline in incidence, the potential for future circulation and the absence of specific antivirals underscore continued scientific interest in prophylactic vaccine development. To synthesize evidence from clinical trials regarding the safety and preliminary immunogenicity of current ZIKV vaccine candidates. This systematic review followed PRISMA guidelines (CRD420251056463). Searches were performed in MEDLINE, Embase, Web of Science, SciELO, and LILACS for clinical trials published between 2015 and 2025. Risk of bias was assessed using the Cochrane RoB 2 tool. Ten Phase 1 clinical trials were included, evaluating four platforms: inactivated virus (ZPIV, TAK-426, VLA1601), DNA (GLS-5700, VRC5283), mRNA (mRNA-1325, mRNA-1893), and viral vector (Ad26.ZIKV.001). All candidates demonstrated acceptable safety profiles, with predominantly mild-to-moderate and transient adverse events (e.g., injection site pain, fatigue, and headache); no vaccine-related serious adverse events were reported. Most platforms induced robust neutralizing antibody responses. Specifically, TAK-426 showed immune persistence for up to two years, while mRNA-1893 maintained responses for 13 months. The viral vector vaccine (Ad26.ZIKV.001) achieved 100% seroconversion with a single dose. Previous orthoflavivirus exposure did not significantly hinder vaccine-induced immunogenicity. Most studies presented a low risk of bias. ZIKV vaccine candidates across diverse technological platforms are safe and highly immunogenic. The evidence of long-term durability and the success of single-dose or mRNA regimens support the progression of the most promising candidates to Phase 2/3 trials.
2026-04-01 | Integrative immunogenomic strategy for designing a multi-epitope vaccine against Zika and Dengue viruses.
Two of the most prevalent illnesses spread by mosquitoes are the Dengue virus (DENV) and the Zika virus (ZIKV), both of which belong to the Flaviviridae family. Co-infection with ZIKV and DENV has been reported worldwide, sometimes with dire consequences. Developing a single vaccine capable of protecting against both pathogens would therefore be highly beneficial. In this research, an in-silico immunology strategy was employed to construct a multi-epitope, multi-pathogen vaccine targeting both viruses. Considering that DENV and ZIKV share the same mosquito vector, Aedes aegypti, and that its salivary proteins can facilitate viral infection, eleven CTL epitopes, five B-cell antigenic determinants, and twelve HTL epitopes were chosen for the final vaccine. Our DENV and ZIKV vaccine have 567 amino acids and molecular mass is 58603.84 amu. An in-silico 3D modelling process and a structural explanation of the model followed docking and dynamics simulations utilizing human TLR7 and TLR5 with docking scores of -392.81 and − 370.88, respectively. The immune reaction simulation suggests that the suggested vaccination may cause a significant immune response that can protect against both DENV and ZIKV.
antibodies
2026-08-14 | Activation and Inhibition of Autophagy and the Lysosome: Potential Therapeutic Avenues for Prenatal Zika Virus Infection
Zika virus (ZIKV), a mosquito-borne flavivirus, has been found in 87 countries and territories. Global outbreaks peaked in 2016. Prenatal Zika virus infection was found to be associated with microcephaly, arthrogryposis, intracranial calcifications, fetal growth restriction, and fetal demise. The most severely affected children were diagnosed with congenital Zika syndrome, which impacts thousands worldwide. With no approved treatment or preventative measures for Zika virus, future viral outbreaks have the potential to cause epidemic levels of prenatal brain injury, as seen over the past 70 years. Therefore, there is a great need for a reliable and clinically translational experimental system that mimics the human condition of prenatal Zika virus infection. To this end, we developed a novel, humanized, immunocompetent preclinical system of virally induced brain injury from prenatal Zika virus infection, which ranges from mild to severe. Here, we describe the extent to which this system mirrors the human phenotypic spectrum. Using our thorough preclinical system, we find that prenatal Zika virus infection of mice impacts survival rate, anthropometric measurements, tissue formation, and neurological outcomes, all of which are typically affected by prenatal infection. Current and future applications include the identification of genetic or environmental modifiers of brain injury, molecular or mechanistic studies of pathogenesis, and preclinical evaluation of future therapies.
2026-08-07 | Generation and characterization of an anti ITGB4 monoclonal antibody that blocks Zika virus entry.
Zika virus (ZIKV) causes congenital disease and neurological complications, yet no approved vaccines or antivirals are available. Integrin β4 (ITGB4) has been identified as an entry receptor for ZIKV. Recombinant human ITGB4 ectodomain was expressed using a baculovirus-insect cell system and used to immunize BALB/c mice. Hybridoma screening identified monoclonal antibody 7C3. Binding affinity to ITGB4 was determined by biolayer interferometry. Epitope relationships between 7C3 and the previously reported anti-ITGB4 antibody 13H10 were assessed by competitive binding assay. Antiviral activity was evaluated in four cell lines by RT-qPCR quantification of cell-associated ZIKV RNA after antibody pretreatment and viral challenge. 7C3 bound ITGB4 with picomolar affinity (KD=30.9 pM) and high specificity. Competitive binding showed that 7C3 and 13H10 (KD=7.98 pM) recognize non-overlapping epitopes on ITGB4. Pretreatment with 7C3 significantly reduced cell-associated ZIKV RNA in all four cell lines compared with PBS and isotype controls. A second, independently generated anti-ITGB4 antibody with picomolar affinity can robustly block ZIKV entry across multiple cell types, including SY5Y neuroblastoma cells relevant to congenital neuropathology. The non-overlapping epitopes of 7C3 and 13H10 suggest potential for combination strategies to enhance ITGB4 blockade. High germline identity of the 7C3 variable regions (VH=94.46%, VL=95.82%) supports future humanization. These findings establish 7C3 as a host-directed antiviral candidate and provide a basis for ITGB4-targeting approaches against congenital ZIKV disease.
2026-05-21 | E-protein variability in Zika virus strains: A possible new O-glycosylation site and its implications.
Background and objectives Zika virus (ZIKV) is a flavivirus transmitted by the bite of infected Aedes mosquito. In 2015-16, Brazil reported cases of ZIKV virus infection followed by Guillain-Barre syndrome and congenital birth defects. India has reported ZIKV virus infections sporadically since 2016, without adverse events. This prompted us to conduct this in-silico investigation and identify reasons for this variation. The objective was to study ZIKV envelope protein (E-protein) to identify possible mutations and their potential role in virus entry into the host cell. Methods Using multiple sequence alignments, we compared the genomic sequences from eleven ZIKV strains with maximum genomic data available in the NCBI database, followed by phylogenetic analysis. ZIKV E-protein structures with mutations were generated using AlphaFold and used for molecular dynamic simulation, followed by protein 3D structure and residues interaction analysis. Results We identified 2 major ZIKV clades - ZIKV Senegal strain (African lineage, Accession No. MF510857, 1984) is an ancestral strain representing one clade, while the remaining strains belong to the second major clade, with the Indian strain being closest to the Senegal strain genomically. The Senegal strain also has a significant mutation at residue no. 120 of the E-protein (Alanine to Threonine), which is absent in other strains. Interpretation and conclusions We found a mutation in the ZIKV Senegal strain at residue no. 120 (Alanine Threonine), here Threonine is interacting with Serine residue at position 64. This interaction is known for post-translational O-glycosylation of E-protein, which may reduce the efficacy of envelope-based therapies. To the best of our knowledge, this is the first report of a putative O-glycosylation site on the E-protein of a ZIKV strain, which is an important therapeutic target, and our finding needs further in vitro validation.
2026-05-04 | Dual role of Japanese encephalitis virus fusion loop peptide antibodies in Zika virus infection.
Zika virus (ZIKV) is a key member of the Flavivirus genus that has emerged as a major global public health concern. The fusion loop region (residues 98-110), located within domain II of the envelope protein, is highly conserved among flaviviruses, including ZIKV and Japanese encephalitis virus (JEV). However, the functional consequences of such conservation for cross-reactive immunity remains unclear. Here, we integrated bioinformatic analyses, functional assays in vitro and mouse models in vivo to systematically determine the effects of antibodies directed against the JEV fusion loop (FL) region on ZIKV infection. Sequence alignment and structural analysis revealed complete amino acid identity and almost identical three-dimensional conformations between the FL regions of the two viruses, providing a molecular basis for cross-reactivity. Antisera generated against the JEV FL region recognized ZIKV particles and displayed concentration-dependent bidirectional effects. Increased and decreased antibody levels respectively neutralized viral entry and replication, and facilitated infection via antibody-dependent enhancement (ADE). These effects were confirmed in vivo, in which high and low antibody doses reduced tissue pathology and improved survival, and increased viremia and exacerbated inflammatory responses, respectively. These findings highlight the importance of antibody concentration in determining whether cross-reactive responses to conserved structural elements engender neutralization or enhancement response. Our findings provide experimental evidence for assessing ZIKV susceptibility in JEV-vaccinated populations and offer structural insights for designing flavivirus vaccines that maximize protection while minimizing ADE risk. These findings further highlight potential pathogenic and clinical considerations for optimizing vaccine formulations to reduce cross-reactive enhancement risks.
2026-03-10 | SLC3A2 promotes early-stage of Zika virus infection in human placental cells and astrocytes
Abstract Background: Zika virus (ZIKV) has been associated with neonatal microcephaly or atypical Guillain-Barré syndrome in adults since 2016. However, despite considerable progress in understanding the biology and pathogenesis of ZIKV infection, little is known about its entry factors. This study aimed to identify host-cell proteins essential for ZIKV entry enriched by labeled viral envelope particles. The identification of solute carrier family 3 member 2 (SLC3A2) (CD98 heavy chain) through this approach highlights its potential as a novel target for therapeutic intervention against ZIKV. Methods: Gene editing via CRISPR-Cas9 and classical virological experiments were performed to identify SLC3A2 functions in ZIKV entry and infection processes. Immunofluorescence, quantitative real-time PCR (RT-qPCR), and western blotting technologies were further used to detect viral proteins and genomes. Besides, coimmunoprecipitation and protein/antibody blocking assay were also conducted to identify direct interactions between SLC3A2 and the ZIKV envelope protein. Results: Several human membrane proteins were overexpressed in HEK293 T cells, but only SLC3A2 could significantly promote ZIKV entry into host cells by two- to three- fold compared with the control. During authentic ZIKV infection, the genetic ablation of SLC3A2 in SLC3A2-KO1 JEG-3 cells reduced the viral infection rate to 59.00% ± 5.10% of the wild-type level (100.00% ± 4.97%) ( P < 0.001), but its overexpression increased the susceptibility of human placenta- and brain-derived cell lines to the virus. SLC3A2 overexpression increased attached ZIKV levels to 3.4-fold of the control (3.423 ± 0.715 vs . 1.000 ± 0.897, P < 0.001) and internalized ZIKV levels to 1.7-fold of the control (3.782 ± 0.512 vs . 2.293 ± 0.272, P = 0.013) due to direct interaction with the ZIKV envelope protein in U-251MG cells. Our data further showed the close association of SLC3A2 with the ZIKV envelope protein via its extracellular domain during authentic viral infection. Notably, SLC3A2 ectodomain decoys and blocking antibodies markedly reduced ZIKV infection rather than affecting influenza A virus infection. Conclusion: SLC3A2 promotes ZIKV infection in placenta- or brain-derived cells by directly interacting with the ZIKV envelope protein and improving virus entry. SLC3A2 may be implicated in early-phase ZIKV infection as its entry factor, thereby identifying a potential therapeutic target and a basis for formulating antiviral strategies against ZIKV.
proteins
2026-08-07 | Antiviral efficacy of Trappin-2/Elafin against Zika virus in the human keratinocyte HaCaT cell line.
Zika virus (ZIKV) is primarily transmitted through mosquito bites, and the skin acts as the initial site of viral entry into the host. Consequently, resident skin cells are among the first targets of infection. The epidermis, mainly composed of keratinocytes, can mount an antiviral response against arboviruses through the production of interferons, interferon-stimulated genes, cytokines, and antimicrobial peptides (AMPs), including the Trappin-2/Elafin (Tr2/E) peptide. However, the antiviral activity of Tr2/E during ZIKV infection remains poorly understood, therefore, this study aimed to investigate the antiviral activity of Tr2/E in human keratinocytes during ZIKV infection. In this study, we evaluated the permissiveness of the human keratinocyte cell line HaCaT to infection with a Mexican isolate of ZIKV and observed that these cells support productive viral infection. We then assessed whether ZIKV infection induces endogenous expression of Tr2/E. Tr2/E transcripts were detected in infected cells and showed increased expression over time post-infection, which correlated with the presence of its corresponding protein. Furthermore, we evaluated the antiviral potential of this peptide through exogenous treatment of infected keratinocytes. A significant reduction in ZIKV infection following Tr2/E treatment was observed. Collectively, these findings provide additional insight into the involvement of AMPs in the antiviral response to ZIKV infection and highlight Tr2/E as a potential antiviral factor.
2026-06-09 | Human dermal fibroblast-derived factors from sequential DENV-2 and ZIKV coinfection drive dendritic cell maturation and antiviral responses.
Dengue virus (DENV) and Zika virus (ZIKV) are among the most prevalent mosquito-borne viruses worldwide. These viruses co-circulate in the same geographical regions and share the same mosquito vectors, enabling concurrent or sequential transmission to humans within a short period. During the early phase of arbovirus infection, skin-resident cells constitute the first line of defense following viral inoculation, yet the immunological events in the skin microenvironment during early DENV-ZIKV coinfection are not well understood. This study aimed to investigate the response of primary human dermal fibroblasts (HDFs) to DENV-ZIKV coinfection and to determine how these responses influence bystander immune cells within an in vitro. We demonstrated that sequential infection with DENV-2 followed by ZIKV significantly increased the expression of pro-inflammatory cytokines (IL-6, IL-8, IL-1β), leukocyte migration-associated chemokine (CXCL10), and antiviral mediators (IFN-β and IFN-λ) in HDFs. Primary monocyte-derived dendritic cells (moDCs) exposed to soluble mediators from sequentially coinfected HDFs exhibited greater activation marker expression compared with simultaneous coinfection or monoinfection conditions. Furthermore, these mediators conferred antiviral effects against both DENV-2 and ZIKV infection in treated moDCs. These findings highlight the important role of dermal fibroblasts in shaping adaptive immunity and limiting viral spread during DENV and ZIKV coinfection.
2026-05-29 | ACSS2-mediated MYH9 crotonylation drives Zika virus-induced vascular smooth muscle cell phenotypic switching.
Zika virus (ZIKV) infection represents an emerging cause of cardiovascular pathology, yet the molecular mechanisms driving virus-induced vascular injury remain incompletely defined. This investigation identifies a crotonylation pathway underlying ZIKV-induced vascular disease. We demonstrate that ZIKV infection upregulates the metabolic regulator ACSS2, consequently elevating intracellular crotonyl-CoA levels. This metabolic shift drives lysine crotonylation of the cytoskeletal protein MYH9 at the critical K82 residue, triggering a pathological transition of vascular smooth muscle cells from contractile to synthetic phenotypes. This cellular reprogramming promotes aortic injury across multiple animal models, including northern pig-tailed macaques and A129 mice. Genetic ablation of ACSS2 substantially attenuated both the phenotypic switching and disease progression. Furthermore, we developed a targeted therapeutic peptide that effectively inhibits MYH9-K82 crotonylation and mitigates pathological vascular remodeling. These findings not only elucidate ACSS2-mediated protein crotonylation as a fundamental mechanism in ZIKV-induced vasculopathy but also present a promising precision therapeutic strategy for treating virus-induced proliferative vascular diseases.
2026-03-31 | Breaking barriers and beyond: Mechanisms and pathological implications of Zika virus traversal across blood-tissue interfaces.
Blood-tissue barriers are specialized interfaces that safeguard organ homeostasis by restricting pathogen dissemination. Zika virus (ZIKV), an emerging flavivirus of global concern, exhibits an exceptional ability to breach multiple barriers-including the blood-brain, blood-placental, blood-testis, and blood-retinal barriers-enabling neuroinvasion, vertical and sexual transmission, and ocular disease. ZIKV employs diverse strategies to cross these barriers: receptor-mediated entry, disruption of tight junctions, and hijacking immune cells or extracellular vesicles as viral carriers. Adaptive mutations further refine tissue tropism and enhance barrier traversal efficiency. Insights from cell culture, organoid, animal, and ex vivo tissue models reveal not only the conserved and tissue-specific mechanisms of barrier penetration but also the downstream pathological consequences in the affected organs. Understanding how ZIKV breaches these interfaces and induces organ-specific pathology deepens our knowledge of host-pathogen interactions and provides a framework for designing barrier-protective and disease-mitigating strategies against ZIKV and other pathogens that breach blood-tissue barriers.
2026-02-09 | Interferon lambda signaling to maternal dendritic cells protects against congenital Zika virus infection.
Interferon lambda (IFN-λ, type III IFN) mediates antiviral immunity at anatomic barriers, including the maternal-fetal interface. To investigate the effects of IFN-λ during congenital Zika virus (ZIKV) infection, we infected mice lacking the IFN-αβ receptor (Ifnar1 -/-) or both the IFN-αβ and IFN-λ receptors (Ifnar1 -/- Ifnlr1 -/-) at E9 and found that loss of maternal IFN-λ signaling resulted in greater transplacental transmission. We used HiPlex RNAscope on entire gravid uteruses and found that IFN-λ was expressed more proximal to the site of ZIKV infection in Ifnar1 -/- dams compared to Ifnar1 -/- Ifnlr1 -/- dams. We performed immunophenotyping of the placenta and uterus by flow cytometry and found a decrease in dendritic cells and NK cells in the uterus of Ifnar1 -/- Ifnlr1 -/- dams compared to Ifnar1 -/- dams, but NK cell depletion did not impact fetal infection. Using conditional knockout mice, we identified maternal dendritic cells as the key IFN-λ responsive cell type mediating protection against ZIKV congenital infection.
other
2026-08-21 | Tunneling nanotubes contribute to Zika virus pathogenesis at the maternal-fetal interface in vivo.
Zika virus (ZIKV) infection during pregnancy can result in severe fetal outcomes, yet the mechanisms of transplacental dissemination remain incompletely defined. We previously showed that ZIKV induces tunneling nanotubes (TNTs), actin-rich intercellular conduits that enable direct cell-to-cell transfer of viral components. Here, we investigated the in vivo role of TNTs in ZIKV maternal-fetal transmission using complementary pregnancy models. A TNT-deficient ZIKV mutant (ZIKVΔTNT), harboring a change between residues 40 and 52 of the nonstructural protein 1 (NS1), showed markedly reduced viral dissemination to maternal and fetal tissues across all models tested, whereas the TNT-competent ZIKV established a robust infection. ZIKVΔTNT infection was associated with reduced placental pathology, altered junctional-to-labyrinth architecture, improved placental efficiency, and protection from fetal growth restriction. Loss of TNT-forming capacity also limited viral persistence despite maternal type III interferon (IFN-λ) responses, suggesting a role for TNTs in immune evasion. Together, these findings provide in vivo evidence that TNTs are a key mechanism by which ZIKV enhances dissemination, promotes placental dysfunction, and drives fetal pathogenesis.IMPORTANCEZika virus infection during pregnancy can cause severe fetal abnormalities, yet how the virus overcomes the placenta remains incompletely understood. Here, we show that ZIKV exploits direct intercellular connections called tunneling nanotubes (TNTs) to facilitate cell-to-cell transmission and impact placental infection and fetal outcomes. Using multiple pregnancy models, we demonstrate that viruses capable of forming these structures disseminate more efficiently, damage the placenta, and lead to fetal growth restriction, whereas TNT-deficient viruses show reduced infection and milder disease. Importantly, TNT-mediated dissemination is associated with viral persistence despite maternal interferon responses, suggesting a role in immune evasion. These findings identify TNTs as a previously underappreciated pathway of viral transmission during pregnancy and suggest new therapeutic targets. More broadly, TNTs may contribute to the pathogenesis of other vertically transmitted or emerging viral infections.
2026-06-06 | Zika virus as an oncolytic therapy.
Glioblastoma (GBM) is a common, aggressive, primary brain tumor. New therapies are needed to improve outcomes in patients with this disease. One such approach which has shown preclinical promise is the use of genetically engineered Zika virus for oncolytic virotherapy. Zika virus is an enveloped, positive-sense, single-stranded RNA virus and is spread by mosquitoes of the Aedes genus. Most infections with Zika virus in adults are asymptomatic. However, primary infection with Zika virus early during pregnancy can cause fetal congenital defects. This phenomenon, termed congenital Zika syndrome, is thought to be the result of infection of fetal neural stem cells. The development of Zika virus as an oncolytic for GBM arose from the discovery that Zika virus infects and kills GBM stem cells. GBM stem cells have similarities to fetal neural stem cells and are a subpopulation of cells within the tumor that are refractory to treatment and likely drive tumor persistence and re-occurrence. In preclinical models of GBM, infection with Zika virus triggers immune-mediated clearance of orthotopically transplanted tumors and leads to development of immunological memory. The propensity of Zika virus to infect GBM stem cells along with limited systemic toxicities and transmissibility make Zika virus an ideal candidate for development as an oncolytic therapy.
2026-05-21 | A CRISPR activation screen identifies SPART as a pan-orthoflavivirus restriction factor.
Orthoflaviviruses, including Zika (ZIKV), dengue, Japanese encephalitis, and West Nile viruses, cause diverse clinical syndromes and threaten human health. Identifying factors that inhibit orthoflavivirus infection could lead to antiviral countermeasures. Here, we conducted a genome-wide CRISPR activation screen and identified the host gene SPART (Spartin/SPG20) as a restriction factor against ZIKV and other orthoflaviviruses. SPART interacts with and disrupts the endosomal localization of Itchy E3-ubiquitin ligase (ITCH), which we determine ubiquitinates the ZIKV capsid, thereby triggering uncoating. Loss of SPART enhances ZIKV replication, an effect not observed in SPART-ITCH double knockout mutants. Maternal ZIKV infection of Spg20-/- mice results in heightened maternal and fetal viral loads and greater fetal abnormalities, whereas infection of Itch-/- mice yields opposite outcomes. Similar results were observed in these gene-edited mice upon infection with related orthoflaviviruses. Overall, this approach identified a broad orthoflavivirus restriction factor, providing a potential target against these emerging pathogenic viruses.
2026-05-15 | MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.
Zika virus (ZIKV) remains a significant public health threat due to its pronounced neurotropism linked to Congenital Zika Syndrome (CZS). Paradoxically, the same neurotropism also provides a unique opportunity for exploiting ZIKV as an oncolytic agent against malignant brain tumors such as glioma. However, achieving precise control of ZIKV replication in specific cell types or tissues remains a major challenge. Here, we show that the brain-specific and enriched microRNA, miR-124, is highly expressed in neural progenitor cells (NPCs) and neurons, but minimally expressed in glioma stem cells (GSCs) and differentiated glioma stem cells (DGCs). Based on these observations, we engineered a recombinant ZIKV containing a miR-124 target sequence (miR-124T) inserted into the 3' untranslated region (UTR) of the viral genome, generating the virus designated ZIKV-miR124T. ZIKV-miR124T exhibited a significantly attenuated phenotype across multiple mouse models, including adult A129 mice, BALB/c neonates, and pregnant mice. Importantly, in an orthotopic glioma model, ZIKV-miR124T retained potent oncolytic activity while showing a markedly improved safety profile. Viral replication was strictly confined in the tumor region, with a ~1,000-fold reduction in viral load in non-tumoral brain regions compared to the well-established live-attenuated ZIKV (ZIKV-LAV). Furthermore, a single immunization with ZIKV-miR124T conferred effective protection against lethal ZIKV challenge and significantly reduced vertical transmission in pregnant mice. Collectively, our findings establish a strong proof of concept for a rational, miRNA-guided strategy to generate a next-generation ZIKV platform with dual potential as a safe live-attenuated vaccine and a precisely regulated oncolytic virus. This study presents a crucial advancement in controlling the safety and function of neurotropic viruses. We engineered a dual-purpose ZIKV, ZIKV-miR124T, which is regulated by the brain-specific microRNA, miR-124. This design forces the virus to strongly self-suppress in healthy neural tissue, solving a major safety concern for ZIKV-based therapies. ZIKV-miR124T is shown to be a potent oncolytic agent against malignant glioma while also serving as a highly effective, safe live-attenuated vaccine against ZIKV infection, reducing vertical transmission to the fetus. Our work provides a strong demonstration of utilizing microRNA regulation to achieve precise viral tropism and attenuation, offering a valuable, generalizable strategy for the development of safer and more effective viral therapies and vaccines against neurotropic pathogens.
2026-04-01 | The Upregulation of Anti-apoptotic BIRC3 Expression Facilitates Zika Virus Infection
Objective: The aim of this study was to investigate the apoptotic gene expression profile and to identify the genes involved in apoptosis and ZIKV infection. Materials and Methods: SH-SY5Y cell line was infected with ZIKV at an MOI of 5. The cells were stained with Annexin V and propidium iodide to determine apoptosis. A real-time polymerase chain reaction array was employed to determine the apoptotic gene expression profile in a ZIKV-infected SH-SY5Y cell line. Western blot analysis was performed to confirm the expression of BIRC3 in both SH-SY5Y and A549 cell lines. Knockdown of the BIRC3 was done in ZIKV-infected A549 cell line using BIRC3 -specific siRNA. The ZIKV production was measured by focus-forming unit assay. Results: Apoptotic genes in both extrinsic and intrinsic pathways, such as TNF-α, TRAIL, FAS, CASP8, CASP9, and BIRC3, were found to be upregulated. The anti-apoptotic gene BIRC3 was selected and found to be upregulated at the protein level in both ZIKV-infected SH-SY5Y and ZIKV-infected A549 cell lines. Knockdown of the BIRC3 gene in ZIKV-infected A549 cell line decreased Zika virus NS1 protein expression and Zika virion production. Conclusion: The upregulation of anti-apoptotic BIRC3 expression facilitates Zika virus infection.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.